Literature DB >> 9021022

The neuroimaging findings in Sotos syndrome.

G B Schaefer1, J B Bodensteiner, B A Buehler, A Lin, T R Cole.   

Abstract

We reviewed the neuroimaging studies of 40 patients with classic Sotos syndrome. The studies consisted of CT scans only in 4 patients and one or more MRI scans in 36 patients. The diagnosis of Sotos syndrome was made using well-established clinical criteria. The neuroimaging studies of each patient were evaluated subjectively by visual inspection and the chief findings were tabulated and grouped into five categories: 1) ventricular abnormalities, 2) extracerebral fluid spaces, 3) midline abnormalities, 4) migrational abnormalities, and 5) others. The most common abnormality of the cerebral ventricles was prominence of the trigone (90%), followed by prominence of the occipital horns (75%) and ventriculomegaly (63%). The supratentorial extracerebral fluid spaces were increased for age in 70% of the patients and the fluid spaces in the posterior fossa were increased in 70% also. A variety of midline abnormalities were noted but anomalies of the corpus callosum were almost universal. Gray matter heterotopias occurred in only 3 (8%) of 36 patients. Periventricular leukomalacia, presumably the result of prenatal or perinatal difficulties and unrelated to the basic condition, was the most common of the miscellaneous other abnormalities noted. The neuroimaging findings of Sotos syndrome are distinct enough to allow differentiation of this syndrome from other mental retardation syndromes with macrocephaly.

Entities:  

Mesh:

Year:  1997        PMID: 9021022     DOI: 10.1002/(sici)1096-8628(19970211)68:4<462::aid-ajmg18>3.0.co;2-q

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  21 in total

1.  Novel missense mutation (L1917P) involving sac-domain of NSD1 gene in a patient with Sotos syndrome.

Authors:  Francesco Nicita; Luigi Tarani; Alberto Spalice; Marina Grasso; Laura Papetti; Massimiliano Cecconi; Claudio Di Biasi; Fabiana Ursitti; Paola Iannetti
Journal:  J Genet       Date:  2011-04       Impact factor: 1.166

Review 2.  Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes.

Authors:  Timothy J Edwards; Elliott H Sherr; A James Barkovich; Linda J Richards
Journal:  Brain       Date:  2014-01-28       Impact factor: 13.501

Review 3.  Overgrowth Syndromes.

Authors:  Andrew C Edmondson; Jennifer M Kalish
Journal:  J Pediatr Genet       Date:  2015-09-25

4.  Isolated macrocerebellum: description of six cases and literature review.

Authors:  Felice D'Arco; Lorenzo Ugga; Ferdinando Caranci; Maria Pia Riccio; Chiara Figliuolo; Kshitij Mankad; Alessandra D'Amico
Journal:  Quant Imaging Med Surg       Date:  2016-10

5.  Macrocerebellum in Achondroplasia: A Further CNS Manifestation of FGFR3 Mutations?

Authors:  H M Pascoe; J Y-M Yang; J Chen; A M Fink; S Kumbla
Journal:  AJNR Am J Neuroradiol       Date:  2019-12-19       Impact factor: 3.825

6.  Macrocerebellum, epilepsy, intellectual disability, and gut malrotation in a child with a 16q24.1-q24.2 contiguous gene deletion.

Authors:  Andrea H Seeley; Mark A Durham; Mark A Micale; Jeffrey Wesolowski; Bradley R Foerster; Donna M Martin
Journal:  Am J Med Genet A       Date:  2014-04-09       Impact factor: 2.802

7.  Bannayan-Riley-Ruvalcaba syndrome: MRI neuroimaging features in a series of 7 patients.

Authors:  R Bhargava; K J Au Yong; N Leonard
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-01       Impact factor: 3.825

Review 8.  Genetic considerations in the prenatal diagnosis of overgrowth syndromes.

Authors:  Neeta Vora; Diana W Bianchi
Journal:  Prenat Diagn       Date:  2009-10       Impact factor: 3.050

9.  The first neurosurgical analysis of 8 korean children with sotos syndrome.

Authors:  Jae Joon Lim; Soo Han Yoon
Journal:  J Korean Neurosurg Soc       Date:  2008-10-30

10.  Sotos syndrome: An interesting disorder with gigantism.

Authors:  A Nalini; Arundhati Biswas
Journal:  Ann Indian Acad Neurol       Date:  2008-07       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.